Evaluating and managing heart disease risk in cancer survivors
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
Baker Heart and Diabetes Institute · NCT05366153
This study is testing a new way to check for heart disease risk in cancer survivors aged 40-70 who had chemotherapy or radiotherapy more than five years ago to see how well it helps manage their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 748 (estimated) |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Sponsor | Baker Heart and Diabetes Institute (other) |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Hobart, Tasmania and 1 other locations) |
| Trial ID | NCT05366153 on ClinicalTrials.gov |
What this trial studies
REDEEM-CAD is a prospective multi-centre study focused on assessing the risk of coronary artery disease (CAD) in cancer survivors aged 40-70 who received chemotherapy or radiotherapy more than five years ago. The study employs a novel clinical and imaging-based screening algorithm to identify individuals at high risk for developing CAD. Participants will undergo follow-up assessments over an average of 36 months, with clinic reviews at 12, 24, and 36 months to monitor their health and manage risk factors effectively. The findings will be compared to data from two existing studies to evaluate the prevalence of subclinical CAD and the efficacy of the screening and management plan.
Who should consider this trial
Good fit: Ideal candidates are cancer survivors aged 40-70 who received chemotherapy or radiotherapy more than five years ago and are at risk for coronary artery disease.
Not a fit: Patients with known coronary artery disease or those who cannot provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention strategies for coronary artery disease in cancer survivors, enhancing their long-term health outcomes.
How similar studies have performed: Other studies have shown success in evaluating CAD risk in cancer survivors, indicating that this approach is promising and builds on existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer). Exclusion Criteria: * Unable to provide written informed consent to participate in this study * Known coronary artery disease at recruitment * History of previous coronary artery disease * Inability to acquire interpretable CT images * Contraindications/Intolerance to or already taking statin therapy * Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Where this trial is running
Hobart, Tasmania and 1 other locations
- Tom Marwick — Hobart, Tasmania, Australia (RECRUITING)
- Baker Heart and Diabetes Institute — Melbourne, Victoria, Australia (RECRUITING)
Study contacts
- Principal investigator: Tom Marwick, MBBS,PhD,MPH — Baker Heart and Diabetes Institute
- Study coordinator: Tom Marwick, MBBS,PhD,MPH
- Email: tom.marwick@baker.edu.au
- Phone: +61 3 8532 1550
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Artery Disease